Drawbridge secures FDA 510(k) Clearance for At-Home Blood Sampling Device NanoDrop

NanoDrop is the First Over-the-Counter Blood-Lancing Device Labeled for the Upper Arm to be Cleared in the United States, Changing the Landscape of the At-Home Consumer Testing Market and Decentralized Clinical Trials

NEW YORK, April 2, 2024 /PRNewswire/ — Drawbridge Health, a healthcare technology company focused on reinventing the blood draw experience, today announced that its at-home, patented blood sampling device, NanoDrop, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Over-the-Counter use. The clearance of this novel dual nano-lancet technology expands a growing suite of products that already includes the OneDraw Collection System, cleared by the FDA as a Class II medical device to collect blood samples to measure HbA1c for monitoring the long-term control of blood sugar (glucose) in diabetic individuals.

NanoDrop is the first over-the-counter blood-lancing device labeled for the upper arm cleared in the United States.
NanoDrop is the first over-the-counter blood-lancing device labeled for the upper arm cleared in the United States.
NanoDrop is a one-of-a-kind, user-friendly lancet that allows individuals to obtain capillary whole-blood samples with a virtually painless, simple press of a button. The cutting-edge technology makes whole-blood sampling and at-home health monitoring both convenient and simple for healthcare professionals and consumers alike.

Sign up for Blog Updates